Skip to main content

ISR’s Report Analyzes Investigator Payments across 11 Therapeutic Areas

By October 30, 2012December 20th, 2021No Comments

Informing the pharmaceutical and biotech industry.

Cary, N.C. – October 30, 2012 – Industry Standard Research (ISR) today announced the availability of their newest report, “Benchmarking Investigator Payments,” which analyzes the level of compensation investigative sites receive for participation in clinical studies.

“Investigator payments can account for over 40% of total trial costs, so it goes without saying that sponsors and CROs can’t afford to get this wrong,” explained Andrew Schafer, President of ISR. “With data from this report, investigator recruitment professionals can identify industry-wide payment averages down to the therapeutic area, phase, and even the type of product being tested.”

“For example, readers of ISR’s report will know that sites conducting Women’s Health studies receive two to six thousand dollars less in compensation per patient, compared to other therapeutic areas,” Schafer continued.

ISR’s report compiles data from 100 principal investigators and site-coordinators responsible for on-site clinical study activities. The report includes in-depth analysis for investigator payments across 11 therapeutic areas, four phases of clinical development, and five types of products (i.e. biologics, biosimilars, ‘me-too’ products, generics, and novel products), as well as analyzes factors that motivate sites’ participation in clinical studies, study characteristics that drive higher fees, and common and preferred investigator payment models.

“One of the interesting findings from this research is the identification of therapeutic areas where specialists dominate. Our analysis enabled us to identify therapeutic areas in which sites typically run a large number of trials, but there are very few sites running trials in that therapeutic area,” Schafer explained. “The bottom line is that knowing more about the site and study characteristics can improve the quality of the feasibility and trial timeline estimates.”

ISR’s report includes an analysis of investigator payments across the following 11 therapeutic areas: Cardiovascular, CNS, Gastrointestinal, Infectious Diseases, Internal Medicine, Metabolic Diseases, Musculoskeletal/Arthritis, Oncology, Pediatric, Respiratory/Allergy, and Women’s Health.

About Industry Standard Research

Industry Standard Research is the premier, full service market research provider to the pharma and pharma services industries.  With over a decade of experience, ISR delivers an unmatched level of domain expertise.  For more information about ISR’s off-the-shelf intelligence and custom research offerings, please visit the company’s Web site at, email, or follow ISR on Twitter @ISRreports.